Loading...
 

Volume 32, Issue 4, December 2021




Sign in to download the Issue in PDF format.

Mediterr J Rheumatol 2021;32(4):376-7
Eosinophilic Fasciitis following Checkpoint Inhibitor Therapy with Pembrolizumab
Authors Information

1. Rheumatology Department, Lefkos Stavros - The Athens Clinic, Athens, Greece

2. 7th Pulmonary Department and Central Bronchoscopic Unit “Christos Gagas” NHS, Athens Chest Hospital "Sotiria", Athens, Greece

E. Zampeli, E. Zervas

Abstract
With the increasing number of indications for checkpoint inhibitor therapy in cancer patients, rheumatology specialists are often involved in the diagnosis and management of immune-related adverse events (irAEs). The most common rheumatic irAEs are arthritis, sicca syndrome, polymyalgia rheumatica, and myositis. Eosinophilic fasciitis, an already rare rheumatic disease, is a very unusual rheumatic irAE. Eosinophilic fasciitis, whether idiopathic or checkpoint inhibitor-associated, has very particular clinical symptoms and findings, such as the orange peel skin appearance and the Groove sign, which the physicians need to be aware of and recognise timely in order to diminish morbidity. 

Article Submitted: 4 Feb 2021; Revised Form: 8 Jul 2021; Article Accepted: 15 Jul 2021; Available Online: 8 Nov 2021

https://doi.org/10.31138/mjr.32.4.376

This work is licensed under a Creative Commons Attribution 4.0 International License. 

©Zampeli Ε, Zervas Ε.